paratext Open Access
Oncotarget
Oncotarget · 2016
Ross-Adams, H✉(Institut pour l'avancée des biosciences)Ball, SLawrenson, K(Indianapolis Zoo)Halim, S(Inserm)Russell, R(Inserm)Wells, CStrand, SHOrntoft, TFLarson, MArmasu, SMassie, CEAsim, MMortensen, MMBorre, MWoodfine, KWarren, AYLamb, ADKay, JWhitaker, HRamos-Montoya, AMurrell, ASorensen, KDFridley, BLGoode, ELGayther, SAMasters, JNeal, DEMills, IG
Abstract
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Funding
- “la Caixa” Foundation
- Fundación Española para la Ciencia y la Tecnología
- Gobierno de Navarra
- Instituto de Salud Carlos III
Citations
381
FWCI
—
field-weighted impact
References
52
Percentile
—
vs. same field & year
Citations per year
References
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Nature Immunology · 2007 · 1,501 citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
New England Journal of Medicine · 2012 · 7,941 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Molecular mechanisms of T cell co-stimulation and co-inhibition
Nature reviews. Immunology · 2013 · 3,032 citations
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation
The Journal of Immunology · 2004 · 1,218 citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 8,055 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.